Bimekizumab Time to Meaningful Improvements in Clinical and Patient-Reported Outcomes in Patients with Psoriatic Arthritis: Results from a Post Hoc Analysis of Two Pooled Phase 3 Studies
Important Information Related to Your Request:
The material below is provided in response to your specific search
for information on UCBCOMPASS® and may
contain information that is not part of the FDA-approved Prescribing
Information. UCB, Inc. does not recommend or endorse the use of its
products in a manner not consistent with the approved Prescribing
Information. Please review the Full Prescribing
Information.